My wife has come a long way with Stage IV lung cancer since 2010. She has now developed acquired resistance to Tarceva.
Gene sequence of biopsy from enlarged pre-vascular and supraclavicular lymph nodes revealed mutation remains EGFR L858R in EXON 21 (original mutation from 2011) and negative to T790M. The cancer is also PD-1 and PD-L1 negative.
Current TAGRISSO indication is for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
My wife was treated with Cisplatinum/vinorabine before she was put on Tarceva in 2011. Is she considered not qualified for Tagrisso being that its no longer her first line treatment?
She is also having a possible reccurence in her brain with new MRI enhancement detected on the resected right occipital lobe. I understand that Tagrisso has a better effectiveness in passing through the BBB. Is she a candidate for using Tagrisso in additional to conventional chemo? What exactly is "first line treatment" defined as?